(Q38913703)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

1 reference

title

Evolving Immunotherapy Approaches for Renal Cell Carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Justine V Cohen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Harriet M Kluger

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

1 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27475806%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11912-016-0542-9

20 March 2020

exact match

0 references

cites work

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Current and future systemic treatments for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Sequential therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Reversing T-cell Dysfunction and Exhaustion in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-016-0542-9

Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study

21 January 2018

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Interferon in metastatic renal cell carcinoma.

1 reference

12 December 2020

Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells

1 reference

12 December 2020

Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results

1 reference

12 December 2020

Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer

1 reference

12 December 2020

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

[CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study]

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

Ipilimumab: a promising immunotherapy for melanoma.

1 reference

12 December 2020

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

12 December 2020